Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, PK/PD, and Clinical Activity of Intravenously Administered KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL

NCT05233033 is registered in ClinicalTrials.gov with Kymera Therapeutics, Inc. as lead sponsor.

NCT NCT05233033
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05233033 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, PK/PD, and Clinical Activity of Intravenously Administered KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL
Lead sponsor
Kymera Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
June 13, 2022
Completion date
July 28, 2023
Enrollment
7 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma, dlbcl, myd88 gene mutation, non hodgkin lymphoma